2016
Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide
Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care 2016, 39: 1127-1134. PMID: 27208332, PMCID: PMC4915555, DOI: 10.2337/dc16-0089.Peer-Reviewed Original ResearchConceptsAdjunctive agentsInsulin deliveryTotal daily insulin doseWeight lossDose escalation periodClosed-loop insulin deliveryDaily insulin dosePlasma glucose excursionsLoop insulin deliveryPrandial insulin deliveryContent of mealsConcomitant bluntingLiraglutide therapyDose titrationLiraglutide treatmentDose escalationInsulin doseGlycemic excursionsGlucose excursionsPostprandial hyperglycemiaPostprandial incrementLiraglutidePramlintideBeneficial effectsEscalation period
2014
Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double‐blind and open‐label cross‐over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验
Tamborlane WV, Renard E, Wadwa RP, Blevins T, Jacober SJ, Liu R, D'Souza DN, Rees TM. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double‐blind and open‐label cross‐over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验. Journal Of Diabetes 2014, 7: 270-278. PMID: 24734891, DOI: 10.1111/1753-0407.12162.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood GlucoseBlood Glucose Self-MonitoringChinaCross-Over StudiesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Double-Blind MethodFemaleFollow-Up StudiesHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulin AspartInsulin Infusion SystemsInsulin LisproMalePostprandial PeriodPrognosisRisk FactorsConceptsContinuous subcutaneous insulin infusionSelf-monitoring blood glucoseTreatment periodCross-over designBlood glucoseDay 6Insulin aspartInsulin lisproMean total daily insulin doseTotal daily insulin doseTotal hypoglycemia rateDaily insulin dosePrimary efficacy measureType 1 DMMean blood glucoseSubcutaneous insulin infusionType 1 diabetesHypoglycemia ratesInsulin doseRandomized trialsEfficacy measuresSMBG profilesInsulin infusionDay 1Two-treatment
2013
A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience
Campbell MS, Schatz DA, Chen V, Wong JC, Steck A, Tamborlane WV, Smith J, Beck RW, Cengiz E, Laffel LM, Miller KM, Haller MJ, Network F. A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience. Pediatric Diabetes 2013, 15: 110-117. PMID: 23957219, PMCID: PMC4164957, DOI: 10.1111/pedi.12067.Peer-Reviewed Original ResearchConceptsGlycemic controlPoor controlMean total daily insulin doseControl groupTotal daily insulin doseExcellent control groupExcellent glycemic controlPediatric type 1 diabetesDaily insulin doseType 1 diabetesPoor control groupMeal-time insulinLong-term riskBlood glucose monitoringDiabetes durationBolus insulinInsulin doseSevere hypoglycemiaRegistry experienceBlood glucoseSelf-management techniquesCare providersParticipants 6Time insulinDiabetes management
2004
A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine
Doyle (Boland) E, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine. Diabetes Care 2004, 27: 1554-1558. PMID: 15220227, DOI: 10.2337/diacare.27.7.1554.Peer-Reviewed Original ResearchConceptsTotal daily insulin doseMultiple daily injectionsType 1 diabetesWeeks of therapyGlargine groupDaily injectionsInsulin aspartMDI treatmentShort-term studiesContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyContinuous subcutaneous insulin infusionSelf-monitoring blood glucoseDaily insulin doseSelf-monitored blood glucose measurementsInsulin infusion therapySubcutaneous insulin infusionBlood glucose readingsSelf-monitored blood glucose readingsBlood glucose measurementsDaily glargineCSII groupDose titrationProspective trialAdverse events